Primary Progressive Aphasia (PPA) is a neurodegenerative disorder characterized by progressive loss of language abilities, while other cognitive functions remain relatively preserved for at least two years[1]. Treatment approaches focus on speech and language therapy, pharmacological interventions, and supportive management strategies.
Speech and language therapy forms the cornerstone of PPA management, though it differs from aphasia treatment post-stroke due to the progressive nature of the disorder[2].
Key Approaches:
Compensatory Strategies
Maintenance Therapy
Life Participation Approach
The efficacy of speech therapy in PPA varies by subtype, with semantic variant PPA often showing less response than nonfluent/agrammatic variant[3]. Intensive, personalized therapy programs yield better outcomes than standard protocols.
No FDA-approved medications specifically target PPA. However, several off-label approaches have been investigated[4]:
NMDA Receptor Antagonists
Novel Approaches
Communication Environment Optimization
Caregiver Support and Training
Lifestyle Modifications
Transcranial Magnetic Stimulation (TMS)
Transcranial Direct Current Stimulation (tDCS)
Speech-Generating Devices
PPA typically progresses over 10-15 years, with eventual involvement of other cognitive domains in most cases[6]. Treatment goals evolve:
Mesulam, M. M. (2001). Primary progressive aphasia. Annals of Neurology. 2001. ↩︎
Taylor, C., & Croot, K. (2014). Speech and language therapy approaches to managing primary progressive aphasia. Practical Neurology. 2014. ↩︎
Jokel, R., et al. (2019). Journal of Speech, Language, and Hearing Research. 2019. ↩︎
Vandenbulcke, M., et al. (2020). Journal of Alzheimer's Disease. 2020. ↩︎
Harciarek, M., & Kertesz, A. (2011). Primary progressive aphasias and their contribution to the understanding of Alzheimer's disease. Frontiers in Neurology. 2011. ↩︎